EUVIMEDEUVIMED entdecken
Crossref

Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?

Emilio José Narváez-Fernández, Ana Entrala, Ana Nin-Valencia, Patricia Mir-Ihara, Itsaso Losantos-García, Javier Domínguez-Ortega, María Ángeles González-Fernández, Santiago Quirce, Natalia Hernández-Cano, Rosario Cabañas, Teresa Caballero

International Archives of Allergy and Immunology · 2023

DOI: 10.1159/000530494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2023. Verfasst von Emilio José Narváez-Fernández und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria, Chronic Urticaria, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics have revolutionized the treatment of many diseases. In this regard, omalizumab (OMA), an anti-IgE monoclonal antibody, is the recommended therapeutic option for patients with chronic spontaneous urticaria (CSU) refractory to second-generation H1-antihistamines. Several studies confirm the efficacy and safety of the drug. However, the literature focusing on the elderly population is scarce, as this age group is often excluded from clinical trials. Therefore, the pharmacological treatment of CSU in elderly patients is a challenge that is increased by their comorbidities and consequent polypharmacy.

Objectives

We describe the real-life safety profile of OMA in elderly patients (≥70 years) with CSU and chronic inducible urticaria (CIndU). We aimed to provide data for daily clinical practice in this vulnerable patient group.

Method

A retrospective review was performed of the records of patients with CSU/CIndU from May 2003 to December 2019 in the Hospital Universitario La Paz. We describe qualitative and quantitative data according to measures of central tendency. Comparisons between qualitative and quantitative data were performed with the Mann-Whitney U test and the Fisher’s test for qualitative variables. A p value <0.05 was considered statistically significant. Results and Conclusions: Eighty-nine patients were included, divided into two groups (<70 vs. ≥70 years). The overall rate of adverse events (AEs) was 48%, mainly mild. No association between age and AE was found (p = 0.789). No serious AE such as anaphylaxis was detected. CSU predominated in both groups. CIndU was less prevalent in the elderly (p = 0.017). There was no association between age and the other variables. Although the frequency of neoplasms was slightly higher in the elderly with OMA, we found no difference compared to the incidence of neoplasms in the general population. Therefore, our data suggest that OMA may be a safe treatment in elderly people with CSU/CIndU for prolonged periods of treatment, although further studies with larger samples are needed to corroborate our observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsUrticariaChronic UrticariaNeoplasmsHumansAgedOmalizumabChronic DiseaseImmunosuppressive AgentsChronic Inducible UrticariaTreatment Outcome

Stichwörter der Autor:innen

Adverse eventsChronic inducible urticariaChronic spontaneous urticariaElderlyOmalizumabSafety profileTreatment

Substanzen

OmalizumabAnti-Allergic AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Allergy, Hospital Universitario La Paz, Madrid, Spain.
  • Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain.
  • Biostatistics Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
  • CIBERES, CIBER of Respiratory Diseases, Madrid, Spain.
  • Department of Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.

Zitieren

APA

Narváez-Fernández, E. J., Entrala, A., Nin-Valencia, A., Mir-Ihara, P., Losantos-García, I., Domínguez-Ortega, J., González-Fernández, M. Á., Quirce, S., Hernández-Cano, N., Cabañas, R., & Caballero, T. (2023). Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?. International Archives of Allergy and Immunology. https://doi.org/10.1159/000530494

Vancouver

Narváez-Fernández EJ, Entrala A, Nin-Valencia A, Mir-Ihara P, Losantos-García I, Domínguez-Ortega J, et al. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?. International Archives of Allergy and Immunology. 2023. doi:10.1159/000530494

BibTeX
@article{NarvezFernndez2023,
  author = {Narváez-Fernández, Emilio José and Entrala, Ana and Nin-Valencia, Ana and Mir-Ihara, Patricia and Losantos-García, Itsaso and Domínguez-Ortega, Javier and González-Fernández, María Ángeles and Quirce, Santiago and Hernández-Cano, Natalia and Cabañas, Rosario and Caballero, Teresa},
  title = {Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?},
  journal = {International Archives of Allergy and Immunology},
  year = {2023},
  doi = {10.1159/000530494}
}
Kostenlos starten →